BIOMAT Database Logo BIOMAT Database Logo

[A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and CVD regimen]. 1994

O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
Department of Urology, Kyoto Prefectural University of Medicine.

A 44-year-old male had multiple metastasis to the lung, liver, kidney and paraaortic lymph node from primary adrenal malignant pheochromocytoma. Radiation therapy with 131I-metaiodobenzylguanidine (131I-MIBG), was first performed, which was followed by chemotherapy with cyclophosphamide, vincristine and dacarbazine (CVD). A total amount of 4810 MBq of 131I-MIBG was administered then 7 cycles of CVD regimen were added. He was survived for sixteen months with tumor response in primary tumor, paraaortic lymph node and liver metastasis tumors, in addition to hormonal response. It was considered that the survival was prolonged in spite of advanced case with inoperative primary tumor.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D008297 Male Males
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
A case of malignant pheochromocytoma treated by 131I-metaiodobenzylguanidine.
January 1988, Acta oncologica (Stockholm, Sweden),
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
A case of malignant pheochromocytoma treated with 131I-metaiodobenzylguanidine and alpha-methyl-p-tyrosine.
January 1990, Japanese journal of medicine,
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma.
May 1994, Annals of nuclear medicine,
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
[131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
October 2005, The Journal of clinical endocrinology and metabolism,
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
[131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
Treatment of a malignant pheochromocytoma in a dog using 131I metaiodobenzylguanidine.
January 2011, Journal of the American Animal Hospital Association,
O Ukimura, and M Kojima, and S Hosoi, and H Itoh, and H Watanabe, and T Minamikawa
High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
July 2003, Cancer,
Copied contents to your clipboard!